[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342912-105":59,"doc-detail-342912-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","strategies-and-recent-advances-on-improving-efficient-antitumor-of-lenvatinib-based-on-nanoparticle-delivery-system-review","Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System - Review","","Lenvatinib (LVN) is a multiple-targeted receptor tyrosine kinase inhibitor approved for hepatocellular carcinoma, metastatic renal cell carcinoma, and thyroid cancer, yet limited therapeutic performance remains due to poor water solubility, rapid metabolism, complex tumor microenvironment, and drug resistance. This review summarizes how nanotechnology-based LVN delivery can enhance antitumor activity through active targeting, controllable release, and biomimetic strategies. It highlights longer-term efficacy, combination therapy, diagnostic and tracking applications, and toxicity reduction, noting potential to address multidrug resistance and improve synergistic outcomes using photothermal, photodynamic, and immunoregulatory approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/strategies-and-recent-advances-on-improving-efficient-antitumor-of-lenvatinib-based-on-nanoparticle-delivery-system-review/342912/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/strategies-and-recent-advances-on-improving-efficient-antitumor-of-lenvatinib-based-on-nanoparticle-delivery-system-review/342912.png","ImageObject",300,407,{"name":92,"@type":93},"Violet","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is lenvatinib’s therapeutic efficacy limited?","Question",{"text":112,"@type":113},"Poor pharmacokinetic behavior, including low water solubility and rapid metabolism, together with a complex tumor microenvironment and drug resistance, reduces satisfactory therapeutic efficacy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do nanoparticle delivery systems improve lenvatinib antitumor effects?",{"text":117,"@type":113},"Nanoparticle systems enable active targeting, controllable drug release, and biomimetic strategies to deliver LVN to tumor sites more effectively, compensating for limited passive targeting.",{"name":119,"@type":110,"acceptedAnswer":120},"What additional strategies can enhance antitumor outcomes beyond delivery?",{"text":121,"@type":113},"Combining LVN with therapies such as photothermal, photodynamic, and immunoregulatory approaches may overcome multidrug resistance, regulate unfavorable tumor microenvironment, and increase synergistic antitumor effects.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342912,1790193844,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","International Journal of Nanomedicine Dovepress  \nopen access to scientific and medical research  \n Open Access Full Text Article REVIEW  \nStrategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System  \nHaiqing Wang 1 , *, Wentao Bo 1 , *, Xielin Feng 1 , Jinliang Zhang 1 , Ge Li2 , Yan Chen 3  \n1Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 2Department of Emergency, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China; 3Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Yan Chen; Ge Li, Email [cyfy1112@163.com](cyfy1112@163.com); [chenyanyaoxuebu@scszlyy.org.cn](chenyanyaoxuebu@scszlyy.org.cn); [13982129787@qq.com](13982129787@qq.com)  \n\n| Abstract: Lenvatinib (LVN) is a potentially effective multiple-targeted receptor tyrosine kinase inhibitor approved for treating hepatocellular carcinoma, metastatic renal cell carcinoma and thyroid cancer. Nonetheless, poor pharmacokinetic properties including poor water solubility and rapid metabolic, complex tumor microenvironment, and drug resistance have impeded its satisfactory therapeutic efficacy. This article comprehensively reviews the uses of nanotechnology in LVN to improve antitumor effects. With the characteristic of high modifiability and loading capacity of the nano-drug delivery system, an active targeting approach, controllable drug release, and biomimetic strategies have been devised to deliver LVN to target tumors in sequence, compensating for the lack of passive targeting. The existing applications and advances of LVN in improving therapeutic efficacy include improving longer-term efficiency, achieving higher efficiency, combination therapy, tracking and diagnosing application and reducing toxicity. Therefore, using multiple strategies combined with photothermal, photodynamic, and immunoregulatory therapies potentially overcomes multidrug resistance, regulates unfavorable tumor microenvironment, and yields higher synergistic antitumor effects. In brief, the nano-LVN delivery system has brought light to the war against cancer while at the same time improving the antitumor effect. More intelligent and multifunctional nanoparticles should be investigated and further converted into clinical applications in the future.\u003Cbr>Keywords: lenvatinib, nano-drug delivery system, antitumor, side effects, diagnosis |\n| --- |\n| Introduction\u003Cbr>Cancer remains the most common disease and one of the leading causes of death due to a high incidence and late diagnosis. The commonly used treatment methods include surgery, radiotherapy, chemotherapy, targeting therapy, and immunotherapy. With advances in targeted therapeutics, survival rates have significantly improved for numerous advanced-stage cancers, including hepatocellular carcinoma (HCC), colorectal cancer and gastric cancer. Lenvatinib (LVN), as a multiple-targeted receptor tyrosine kinase inhibitor, 1–3 has been approved for several cancers by the American Food and Drug Administration, including HCC,4 thyroid cancer5 and metastatic renal cell carcinoma.6 Ina Phase 2 randomized, open, multicenter trial,6 LVN was administered orally, alone or with everolimus, for treatment of progressive metastatic renal cell carcinoma as second-line treatment. The overall survival was not significantly different, LVN alone or combined with everolimus groups had a higher objective response rate and ","cbCaidfh0wtzWFEc","https://ap.wps.com/l/cbCaidfh0wtzWFEc","pdf",7310525,23,"English","# Abstract\n# Introduction","[{\"question\":\"Why is lenvatinib’s therapeutic efficacy limited?\",\"answer\":\"Poor pharmacokinetic behavior, including low water solubility and rapid metabolism, together with a complex tumor microenvironment and drug resistance, reduces satisfactory therapeutic efficacy.\"},{\"question\":\"How do nanoparticle delivery systems improve lenvatinib antitumor effects?\",\"answer\":\"Nanoparticle systems enable active targeting, controllable drug release, and biomimetic strategies to deliver LVN to tumor sites more effectively, compensating for limited passive targeting.\"},{\"question\":\"What additional strategies can enhance antitumor outcomes beyond delivery?\",\"answer\":\"Combining LVN with therapies such as photothermal, photodynamic, and immunoregulatory approaches may overcome multidrug resistance, regulate unfavorable tumor microenvironment, and increase synergistic antitumor effects.\"}]","Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System - Review | PDF",1790048783,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf2da7574fb547774e3ef1cbba6b7519.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d0a4adce4bfbce5d58e7767c42768b1.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dee87674be88c5c98c2bcc712cdc90f1.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b42ba68dd0e7f2a8e42a56a9a03127c.webp",980,1268]